PepGen Inc. (PEPG) - Return on Sales by Gross Profit

PEPG (PepGen Inc.) - company brandmark

PepGen Inc. relies on a strong team of RNA platform developers and the active recruitment of clinical-stage managers. The gross margin share demonstrates financial stability, with the current figure standing at 0.00. This is supported by strict discipline from top management and transparent reporting. Meanwhile, demand for gene therapy remains independent of economic conditions, as business development is dictated exclusively by biological needs.

pepgen.com - PEPG Gross Margin (period 04/28/2023 - 11/20/2026)

Financial and market metric breakdowns for PepGen Inc (PEPG)

- price and consensus price forecast:
Basic company analysis:PepGen Inc.
Product sample of PepGen

The investment attractiveness of PepGen Inc. (PEPG) is based on the potential of RNA therapy, although the absence of commercial products renders operational efficiency secondary. This indicator measures the share of revenue minus direct production costs, while changes in the gross margin reflect the cost of maintaining clinical developments. The stability of this metric confirms the company's ability to control costs amidst negative cash flow.

Direct competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|Return on Gross Profit Neumora NMRA|Gross Profitability Scilex Holding Company, Inc. SCLX|Gross Sales Margin Tevogen Bio Inc.|ACOG - Gross Profitability|Gross Sales Margin Cognition Therapeutics (CGTX)|IKT (Inhibikase Therapeutics) - Return on Gross Profit|Cassava Sciences Inc (SAVA) - Gross Margin|Return on Gross Profit ASRT|Gross Margin coyatherapeutics.com|Gross Margin VTGN|Ovid Therapeutics - Gross Return on Sales|Gross Margin ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Return on Gross Profit|ATHE - Gross Profitability|Return on Sales by Gross Profit clene.com CLNN|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)